4.2 Article

Activity and Capacity Profile of Transplant Physicians and Centers in Australia and New Zealand

期刊

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 24, 期 1, 页码 169-174

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2017.09.011

关键词

Hematopoietic; Cell; Transplantation; Australia; New Zealand

资金

  1. Bone Marrow Transplant Society of Australia
  2. Bone Marrow Transplant Society of New Zealand
  3. Arrow Bone Marrow Transplant Foundation
  4. St. Vincent's Hospital Sydney
  5. Australian Bone Marrow Donor Registry

向作者/读者索取更多资源

We conducted a study to analyze and report on indicators of hematopoietic cell transplant (HCT) physician time use and HCT center output measures. Ha centers in Australia and New Zealand (A&NZ) were invited to provide demographic and time use details for physicians participating in HCT patient care (HCT physicians). Resource details for adult and pediatric centers were included. From a total of 46 centers that were invited to participate, completed data were received from 37 centers (80%) representing 185 HCT physicians, with a median age of 48 (range, 33 to 72), of whom 31% were women. Just over half of HCT physicians cited prior work experience in large overseas HCT centers (97, 52%) and over one-third (79, 43%) possessed postgraduate qualifications other than specialist training. Total annual mean HCTs per HCT physician full-time equivalent (FTE) were 14.2 for centers performing both allogeneic and autologous HCT, 6.6 for autologous only centers, and 10.6 for all centers. For all HCT physicians surveyed the mean proportion of time spent on HCT related tasks was 31.7%. In A&NZ, for centers that perform both allografts and autografts, there was a mean of 4.0 allogeneic HCT annually per HCT bed, compared with 2.6 for the United States and 7.1 allogeneic HCT annually per HCT physician FTE (United States, 6.3). Projections of the A&NZ HCT physician workforce indicated that the numbers of HCT physicians are likely to stay within the region of 170 to 190 for the next 10 years, whereas HCT activity will likely continue to climb steadily. Healthcare and government authorities should be prepared to enable and support greater HCT activity in A&NZ in the future. (C) 2017 American Society for Blood and Marrow Transplantation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据